NASDAQ:ENTA Enanta Pharmaceuticals - ENTA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $40.44 +1.23 (+3.14%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$39.14▼$40.5750-Day Range$38.82▼$54.5952-Week Range$37.59▼$79.50Volume140,390 shsAverage Volume173,543 shsMarket Capitalization$844.79 millionP/E RatioN/ADividend YieldN/APrice Target$68.60 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Enanta Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.56 Rating ScoreUpside/Downside69.6% Upside$68.60 Price TargetShort InterestBearish4.69% of Float Sold ShortDividend StrengthN/ASustainability-1.11Upright™ Environmental ScoreNews Sentiment1.24Based on 4 Articles This WeekInsider TradingSelling Shares$2.61 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($7.36) to ($0.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.41 out of 5 starsMedical Sector197th out of 1,004 stocksPharmaceutical Preparations Industry85th out of 489 stocks 3.3 Analyst's Opinion Consensus RatingEnanta Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.56, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $68.60, Enanta Pharmaceuticals has a forecasted upside of 69.6% from its current price of $40.44.Amount of Analyst CoverageEnanta Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.69% of the float of Enanta Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEnanta Pharmaceuticals has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Enanta Pharmaceuticals has recently increased by 19.97%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEnanta Pharmaceuticals does not currently pay a dividend.Dividend GrowthEnanta Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEnanta Pharmaceuticals has received a 77.59% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Hepatitis medication", "Clinical research services for physical health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Enanta Pharmaceuticals is -1.11. Previous Next 2.9 News and Social Media Coverage News SentimentEnanta Pharmaceuticals has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Enanta Pharmaceuticals this week, compared to 2 articles on an average week. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enanta Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,612,121.00 in company stock.Percentage Held by Insiders12.70% of the stock of Enanta Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions93.68% of the stock of Enanta Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Enanta Pharmaceuticals are expected to grow in the coming year, from ($7.36) to ($0.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enanta Pharmaceuticals is -6.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enanta Pharmaceuticals is -6.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnanta Pharmaceuticals has a P/B Ratio of 2.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Enanta Pharmaceuticals (NASDAQ:ENTA) StockEnanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.Read More Receive ENTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ENTA Stock News HeadlinesMarch 23, 2023 | americanbankingnews.comEnanta Pharmaceuticals' (ENTA) "Sector Perform" Rating Reaffirmed at Royal Bank of CanadaMarch 22, 2023 | markets.businessinsider.comExpert Ratings for Enanta PharmaApril 1, 2023 | Vantage Point (Ad)Did You See These Trend Reversals?Get ready for a potentially shocking and unprecedented announcement from the Fed meeting on May 3rd. This could cause many retail and industry traders to resort to drastic measures. One swift stroke could make popular assets plummet, BUT… there’s a straightforward solution to act now to protect your family and wealth. March 8, 2023 | finance.yahoo.comEnanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral ResearchMarch 7, 2023 | finance.yahoo.comEnanta Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare ConferenceFebruary 9, 2023 | finance.yahoo.comEnanta Pharmaceuticals First Quarter 2023 Earnings: Beats ExpectationsFebruary 8, 2023 | finance.yahoo.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q1 2023 Earnings Call TranscriptFebruary 8, 2023 | finance.yahoo.comThese Analysts Just Made A Huge Downgrade To Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) EPS ForecastsApril 1, 2023 | Vantage Point (Ad)Did You See These Trend Reversals?Get ready for a potentially shocking and unprecedented announcement from the Fed meeting on May 3rd. This could cause many retail and industry traders to resort to drastic measures. One swift stroke could make popular assets plummet, BUT… there’s a straightforward solution to act now to protect your family and wealth. February 7, 2023 | finance.yahoo.comEnanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2022 with Webcast and Conference Call Today at 4:30 p.m. ETFebruary 7, 2023 | finance.yahoo.comEnanta Pharmaceuticals to Present at the SVB Securities Global Biopharma ConferenceJanuary 31, 2023 | finance.yahoo.comEnanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal First Quarter Ended December 31, 2022January 24, 2023 | nasdaq.comEnanta Pharmaceuticals (ENTA) Shares Cross Above 200 DMAJanuary 16, 2023 | markets.businessinsider.comSVB Securities Keeps Their Hold Rating on Enanta Pharmaceuticals (ENTA)January 10, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Roche Holding AG (OtherRHHVF), Enanta Pharmaceuticals (ENTA) and Day One Biopharmaceuticals (DAWN)January 6, 2023 | finance.yahoo.comAn Intrinsic Calculation For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Suggests It's 49% UndervaluedJanuary 6, 2023 | finance.yahoo.comEnanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2023 Outlook at the 41st Annual J.P. Morgan Healthcare ConferenceJanuary 3, 2023 | finance.yahoo.comEnanta Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 30, 2022 | seekingalpha.comEnanta: Deep Losses In FY 2022 Look To Be Justified Given Macro LandscapeDecember 25, 2022 | finance.yahoo.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q4 2022 Earnings Call TranscriptNovember 23, 2022 | finance.yahoo.comNewsflash: Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Analysts Have Been Trimming Their Revenue ForecastsNovember 22, 2022 | finance.yahoo.comEnanta Pharmaceuticals to Participate in Two Investor Conferences in NovemberNovember 21, 2022 | seekingalpha.comEnanta Pharmaceuticals, Inc. (ENTA) Q4 2022 Earnings Call TranscriptNovember 21, 2022 | finance.yahoo.comEnanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ETNovember 18, 2022 | benzinga.comEarnings Outlook For Enanta PharmaceuticalsNovember 14, 2022 | finance.yahoo.comEnanta Pharmaceuticals to Host Conference Call on November 21 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Fourth Quarter and Full Year Ended September 30, 2022November 9, 2022 | finance.yahoo.comEnanta Pharmaceuticals Initiates SPRINT, a Phase 2 Clinical Trial of EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ENTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ENTA Company Calendar Last Earnings2/07/2023Today4/01/2023Next Earnings (Estimated)5/08/2023Fiscal Year End9/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ENTA CUSIPN/A CIK1177648 Webwww.enanta.com Phone(617) 607-0800Fax617-607-0530Employees155Year FoundedN/APrice Target and Rating Average Stock Price Forecast$68.60 High Stock Price Forecast$96.00 Low Stock Price Forecast$49.00 Forecasted Upside/Downside+69.6%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($5.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-121,750,000.00 Net Margins-146.93% Pretax Margin-147.46% Return on Equity-36.59% Return on Assets-31.85% Debt Debt-to-Equity RatioN/A Current Ratio12.33 Quick Ratio12.33 Sales & Book Value Annual Sales$86.16 million Price / Sales9.80 Cash FlowN/A Price / Cash FlowN/A Book Value$15.51 per share Price / Book2.61Miscellaneous Outstanding Shares20,890,000Free Float18,233,000Market Cap$844.79 million OptionableOptionable Beta0.40 Key ExecutivesJay R. LulyPresident, Chief Executive Officer & DirectorPaul J. MellettCFO & Senior VP-Finance & AdministrationYat Sun OrCSO, Senior Vice President-Research & DevelopmentScott T. RottinghausChief Medical Officer & Senior Vice PresidentNathaniel S. GardinerSecretary, Senior Vice President & General CounselKey CompetitorsKura OncologyNASDAQ:KURACymaBay TherapeuticsNASDAQ:CBAYCrinetics PharmaceuticalsNASDAQ:CRNXCollegium PharmaceuticalNASDAQ:COLLImmunoGenNASDAQ:IMGNView All CompetitorsInsiders & InstitutionsETF Managers Group LLCSold 931 shares on 3/23/2023Ownership: 0.025%Yat Sun OrSold 13,925 sharesTotal: $618,966.25 ($44.45/share)Paul J MellettSold 10,440 sharesTotal: $463,849.20 ($44.43/share)Jay R LulySold 27,912 sharesTotal: $1.26 M ($45.16/share)Teachers Retirement System of The State of KentuckyBought 1,657 shares on 2/22/2023Ownership: 0.029%View All Insider TransactionsView All Institutional Transactions ENTA Stock - Frequently Asked Questions Should I buy or sell Enanta Pharmaceuticals stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last twelve months. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ENTA shares. View ENTA analyst ratings or view top-rated stocks. What is Enanta Pharmaceuticals' stock price forecast for 2023? 9 Wall Street research analysts have issued twelve-month price targets for Enanta Pharmaceuticals' stock. Their ENTA share price forecasts range from $49.00 to $96.00. On average, they anticipate the company's share price to reach $68.60 in the next year. This suggests a possible upside of 69.6% from the stock's current price. View analysts price targets for ENTA or view top-rated stocks among Wall Street analysts. How have ENTA shares performed in 2023? Enanta Pharmaceuticals' stock was trading at $46.52 at the beginning of 2023. Since then, ENTA stock has decreased by 13.1% and is now trading at $40.44. View the best growth stocks for 2023 here. Are investors shorting Enanta Pharmaceuticals? Enanta Pharmaceuticals saw a increase in short interest in March. As of March 15th, there was short interest totaling 900,100 shares, an increase of 20.0% from the February 28th total of 750,300 shares. Based on an average trading volume of 168,700 shares, the days-to-cover ratio is currently 5.3 days. Currently, 4.7% of the company's stock are short sold. View Enanta Pharmaceuticals' Short Interest. When is Enanta Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023. View our ENTA earnings forecast. How were Enanta Pharmaceuticals' earnings last quarter? Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) released its quarterly earnings results on Tuesday, February, 7th. The biotechnology company reported ($1.39) EPS for the quarter, topping analysts' consensus estimates of ($1.52) by $0.13. The biotechnology company earned $23.60 million during the quarter, compared to analyst estimates of $22.48 million. Enanta Pharmaceuticals had a negative trailing twelve-month return on equity of 36.59% and a negative net margin of 146.93%. The company's quarterly revenue was down 14.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.48) earnings per share. What ETFs hold Enanta Pharmaceuticals' stock? ETFs with the largest weight of Enanta Pharmaceuticals (NASDAQ:ENTA) stock in their portfolio include Invesco Dynamic Pharmaceuticals ETF (PJP), Virtus LifeSci Biotech Products ETF (BBP), ETFMG Treatments Testing and Advancements ETF (GERM), Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO), Invesco Nasdaq Future Gen 200 ETF (QQQS), SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU). What is Jay R. Luly's approval rating as Enanta Pharmaceuticals' CEO? 5 employees have rated Enanta Pharmaceuticals Chief Executive Officer Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among the company's employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Enanta Pharmaceuticals to a friend. What other stocks do shareholders of Enanta Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS). What is Enanta Pharmaceuticals' stock symbol? Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA." Who are Enanta Pharmaceuticals' major shareholders? Enanta Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (9.95%), Dimensional Fund Advisors LP (2.60%), Renaissance Technologies LLC (2.27%), Geode Capital Management LLC (1.81%), Braidwell LP (1.56%) and Norges Bank (1.08%). Insiders that own company stock include Bruce L A Carter, Jay R Luly, Nathalie Adda, Paul J Mellett and Yat Sun Or. View institutional ownership trends. How do I buy shares of Enanta Pharmaceuticals? Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Enanta Pharmaceuticals' stock price today? One share of ENTA stock can currently be purchased for approximately $40.44. How much money does Enanta Pharmaceuticals make? Enanta Pharmaceuticals (NASDAQ:ENTA) has a market capitalization of $844.79 million and generates $86.16 million in revenue each year. The biotechnology company earns $-121,750,000.00 in net income (profit) each year or ($5.82) on an earnings per share basis. How many employees does Enanta Pharmaceuticals have? The company employs 155 workers across the globe. How can I contact Enanta Pharmaceuticals? Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The official website for the company is www.enanta.com. The biotechnology company can be reached via phone at (617) 607-0800, via email at cmiceli@enanta.com, or via fax at 617-607-0530. This page (NASDAQ:ENTA) was last updated on 4/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.